Restricted accessResearch articleFirst published online 2016-6
The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized,double-blind,placebo-controlled trial
The objective of this substudy was to examine the effect of desvenlafaxine 50 mg/day compared with placebo on cognitive function in employed outpatients with major depressive disorder. A total of 11/55 (20%) study sites in a 12-week, randomized, double-blind, placebo-controlled trial administered cognitive assessments in memory, attention, and executive functioning domains using the cognitive drug research system. Changes from baseline were subjected to analysis of covariance with baseline levels as covariates, using last observation carried forward data. A significant improvement with desvenlafaxine 50 mg/day (n=52) compared with placebo (n=29) was observed on the quality of working memory composite measure (0.081 units (0.005, 0.156); P=0.0365) at last observation carried forward. Improvement from baseline on the speed of working memory composite was significant for desvenlafaxine (−226.6 msec (−316.7, −136.4); P<0.0001) and for placebo (−133.3 msec (−257.2, −9.4); P=0.0354); however, the treatment effect was not significant. No significant differences between groups were observed on composite measures for attention. Treatment of depression with desvenlafaxine 50 mg/day may improve aspects of cognitive functioning, including working memory.
AdlerDAMcLaughlinTJRogersWH. (2006) Job performance deficits due to depression. Am J Psychiatry163: 1569–1576.
2.
American Psychiatric Association (APA) (2000) DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA.
3.
AustinMPMitchellPGoodwinGM (2001) Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry178: 200–206.
4.
Bang-AndersenBRuhlandTJorgensenM. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem54: 3206–3221.
5.
BeckACrainALSolbergLI. (2011) Severity of depression and magnitude of productivity loss. Ann Fam Med9: 305–311.
6.
BoyerPMontgomerySLepolaU. (2008) Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol23: 243–253.
7.
ClaytonATourianKAFochtK. (2014) Desvenlafaxine 50- and 100-mg/d vs placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry Epub ahead of print 28October2014.
8.
ClaytonAHKornsteinSGDunlopBW. (2013) Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry74: 1010–1017.
9.
CowenPSherwoodAC (2013) The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression. J Psychopharmacol27: 575–583.
10.
DeecherDCBeyerCEJohnstonG. (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther318: 657–665.
11.
Delle ChiaieRSalviatiMFiorentiniS. (2007) Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol15: 563–568.
12.
DunlopBWReddySYangL. (2011) Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol31: 569–576.
13.
EdgarCJongenPJSandersE. (2011) Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurol11: 68.
14.
FergusonJMWesnesKASchwartzGE (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol18: 9–14.
15.
FreyPWColliverJA (1973) Sensitivity and response measures for discrimination learning. Learning Motivation4: 327–342.
16.
FrodlTMeisenzahlEZetzscheT. (2002a) Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry51: 708–714.
17.
FrodlTMeisenzahlEMZetzscheT. (2002b) Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry159: 1112–1118.
18.
FrodlTMeisenzahlEMZetzscheT. (2003) Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry53: 338–344.
19.
FrodlTSchaubABanacS. (2006) Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci31: 316–323.
20.
GreerTLSunderajanPGrannemannBD. (2014) Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?Depress Res Treat2014: 627863.
21.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56–62.
22.
Herrera-GuzmanIGudayol-FerreEHerrera-GuzmanD. (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res43: 855–863.
23.
Herrera-GuzmanIHerrera-AbarcaJEGudayol-FerreE. (2010) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. Psychiatry Res177: 323–329.
24.
HirschfeldRMMontgomerySAAgugliaE. (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry63: 826–837.
25.
IwataNTourianKAHwangE.; for the Study 3359 Investigators (2013) Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients.J Psychiatr Pract19: 5–14.
26.
LamR (2014) Early improvement in depressive symptoms predicts functional improvement in employed adults with major depressive disorder treated with desvenlafaxine 50 mg/d. Int Clin Psychopharmacol29: 239–251.
27.
LeeRSHermensDFPorterMA. (2012) A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. J Affect Disord140: 113–124.
28.
LemkeMR (2002) Effect of reboxetine on depression in Parkinson’s disease patients. J Clin Psychiatry63: 300–304.
29.
LernerDAdlerDAChangH. (2004) Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv55: 1371–1378.
30.
LiebowitzMRManleyALPadmanabhanSK. (2008) Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin24: 1877–1890.
31.
McIntyreRSLophavenSOlsenCK (2014) A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol17: 1557–1567.
32.
MarcotteDEWilcox-GokVRedmonPD (1999) Prevalence and patterns of major depressive disorder in the United States labor force. J Ment Health Policy Econ2: 123–131.
33.
MarshLBiglanKGerstenhaberM. (2009) Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov Disord24: 277–282.
34.
MontgomerySAÅsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
35.
PoyurovskyMKorenDGonopolskyI. (2003) Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol13: 123–128.
36.
RamosBPArnstenAF (2007) Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther113: 523–536.
37.
RaskinJWiltseCGSiegalA. (2007) Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry164: 900–909.
38.
ReitanR (1958) Validity of the trailmaking test as an indication of organic brain damage. Perceptual Motor Skills8: 271–276.
39.
ResslerKJNemeroffCB (2001) Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectrums6: 663–670.
40.
RobinsonMOakesTMRaskinJ. (2014) Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry22: 34–45.
41.
RockwoodK (2004) Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry75: 677–685.
42.
RosenthalJZBoyerPVialetC. (2013) Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry74: 158–166.
43.
RushAJWeissenburgerJVinsonDB. (1983) Neuropsychological dysfunctions in unipolar nonpsychotic major depressions. J Affect Disord5: 281–287.
44.
SheehanDV (2000) Sheehan Disability Scale. In: RushAJPincusHAFirstMB (eds) Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, pp. 113–115.
45.
SinghSPSinghVKarN. (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 197: 174–179.
46.
SoaresCNKornsteinSGThaseME. (2009) Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. J Clin Psychiatry70: 1365–1371.
47.
StahlSM (2009) Stahl’s Illustrated Antidepressants. New York: Cambridge University Press.
48.
StewartWFRicciJACheeE. (2003) Cost of lost productive work time among US workers with depression. JAMA289: 3135–3144.
49.
StroopJR (1935) Studies of interference in serial verbal reactions. J Exp Psychol18: 643–662.
50.
TourianKAPadmanabhanSKGroarkJ. (2009) Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther31 (Pt 1): 1405–1423.
51.
WagnerGKochKSchachtzabelC. (2008) Enhanced rostral anterior cingulate cortex activation during cognitive control is related to orbitofrontal volume reduction in unipolar depression. J Psychiatry Neurosci33: 199–208.
52.
WallaceTLBallardTMPouzetB. (2011) Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav99: 130–145.
53.
WangPSBeckALBerglundP. (2004) Effects of major depression on moment-in-time work performance. Am J Psychiatry161: 1885–1891.
54.
WesnesKPincockC (2002) Practice effects on cognitive tasks: a major problem?Lancet Neurol1: 473.
55.
WesnesKAWardTMcGintyA. (2000) The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl)152: 353–361.
56.
WiseTNWiltseCGIosifescuDV. (2007) The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract61: 1283–1293.
57.
WroolieTEWilliamsKEKellerJ. (2006) Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J Clin Psychopharmacol26: 361–366.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
